Humacyte, Inc. (HUMA)
| Market Cap | 117.54M -62.9% |
| Revenue (ttm) | 2.12M +159.3% |
| Net Income | -96.67M |
| EPS | -0.50 |
| Shares Out | 277.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 882,067 |
| Open | 0.4048 |
| Previous Close | 0.3981 |
| Day's Range | 0.3910 - 0.4300 |
| 52-Week Range | 0.3370 - 1.6800 |
| Beta | 2.68 |
| Analysts | Buy |
| Price Target | 1.63 (+284.07%) |
| Earnings Date | Nov 10, 2026 |
About HUMA
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would tar... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for HUMA stock is "Buy." The 12-month stock price target is $1.63, which is an increase of 284.07% from the latest price.
News
Humacyte Innovative Research in Coronary Bypass and Vascular Regeneration to be Highlighted at American Heart Association Scientific Sessions 2026
– Founder & CEO Laura Niklason, M.D., Ph.D., to deliver invited talk on engineering the microenvironment to accelerate vascular regeneration.
Humacyte To Announce 2026 Third Quarter Financial Results and Provide Business Update on November 10, 2026
DURHAM, N.C, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at comme...
Humacyte issued new U.S. patent covering Symvess
Humacyte (HUMA) announced the issuance of a new U.S. patent covering key aspects of the manufacturing, sterilization, storage and shipping of Symvess and other bioengineered human tissues. U.S. Patent...
Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues
– Patent provides coverage into 2043 for key aspects of how Symvess is manufactured, sterilized, stored and shipped. DURHAM, N.C.
Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner
- The presenter, Dr. Roy-Chaudhury said, “These results give the nephrology community a strong reason to rethink our approach to access decisions for women and, once approved by the FDA, to consider ...
Humacyte says hospitals ordering Symvess rose 44% in Q3 to 49
Humacyte (HUMA) provided a commercial update highlighting increasing momentum in the launch of Symvess, its FDA-approved acellular tissue engineered vessel for vascular trauma. The number of hospitals...
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals
– Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026. – Commercial momentum continues to build, driven...
Humacyte initiated with an Equal Weight at Barclays
Barclays initiated coverage of Humacyte (HUMA) with an Equal Weight rating and 50c price target The firm rolled out coverage of the medical suppliers and devices group with a Positive…
Humacyte announces addition of Coward, Kuznik to board
Humacyte (HUMA) announced the addition of Scott Coward and Paul Kuznik to the Company’s Board of Directors. Scott Coward served as Executive Vice President, Chief Legal Officer, Chief Administrative O...
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at com...
Humacyte Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Symvess, an FDA-approved bioengineered vessel, is expanding from trauma to dialysis and cardiovascular markets, with a supplemental BLA for dialysis access planned for November 2026 and CABG trials starting in 2026. Commercial efforts are being rebuilt, and financial runway extends into late 2027.
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at com...
Humacyte announces FDA extension of expiration dating period for Symvess
Humacyte (HUMA) announced that the FDA has authorized an extension of the expiration dating period for Symvess from 18 months to 36 months when stored refrigerated at 2 degrees C…
Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months
– FDA authorizes extension of Symvess expiration dating from 18 months to 36 months – – Extended shelf life supported by additional stability data demonstrating Symvess continues to meet all establish...
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its...
Humacyte confirms plans for ATEV supplemental biologic license application
Humacyte (HUMA) announced that recent discussions with the FDA confirm the company’s plans and expectations for filing a supplemental biologic license application, or BLA, with the FDA for the acellul...
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 –
Humacyte publishes V007 results in The Lancet Digital Health
Humacyte (HUMA) announced the publication of one-year results from the V007 Phase 3 clinical trial of the acellular tissue engineered vessel in arteriovenous access for hemodialysis patients in The La...
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
– Phase 3 results highlight benefits of ATEV for patients at higher risk of fistula failure, including all women and men with obesity and diabetes –
Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”
– Jeromy Brink, MD, Mayo Clinic–trained vascular surgeon in Phoenix, is the first surgeon in Arizona to implant Symvess, the first and only FDA-approved bioengineered human blood vessel –
Humacyte reports Q2 EPS (16c), consensus (10c)
Reports Q2 revenue $406,000, consensus $1.11M. “Our second quarter and recent weeks have been a transformative period for Humacyte (HUMA) and our pipeline expansion, led by the presentation of breakth...
Humacyte price target lowered to $1 from $2 at Benchmark
Benchmark lowered the firm’s price target on Humacyte (HUMA) to $1 from $2 and keeps a Speculative Buy rating on the shares. tThe near-term adoption rate is difficult to predict…
Humacyte Earnings Call Transcript: Q2 2026
Q2 2026 saw transformative clinical and commercial progress, with strong trial results for ATEV, increased SYMVESS adoption, and a rebuilt commercial team. Financials showed higher sales but continued net losses, while regulatory filings and new studies are on track for late 2026 and 2027.
Humacyte Earnings release: Q2 2026
Humacyte released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Humacyte Quarterly report: Q2 2026
Humacyte has published its Q2 2026 quarterly earnings report on August 12, 2026.